Research progress of MRP3 and MRP4 transporters in tumor

doi:10.12092/j.issn.1009-2501.2019.03.015

Abstract

Abstract:

The study of tumor molecular mechanism has received extensive attention and plays an increasingly important role in the diagnosis and treatment of tumor. MRP family is a transmembrane ATP binding box (ABC) transporter which plays an important role in the study of tumor molecular mechanism. As members of MRP family, MRP3 and MRP4 are novel molecular targets of tumor in recent years and have potential clinical value. Therefore, the structure of MRP3 and MRP4, the role of MRP3 and MRP4 in the diagnosis or treatment and the relevant regulation mechanisms are reviewed in this article to provide new ideas for the future research of tumor.

Key words: MRP3, MRP4, tumor, regulatory mechanism

CLC Number:

ZONG Sidou, ZHANG Hong. Research progress of MRP3 and MRP4 transporters in tumor[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(3): 327-331.

References

［1］Cai C, Omwancha J, Hsieh CL, et al. Androgen induces expression of the multidrug resistance protein gene MRP4 in prostate cancer cells［J］. Prostate Cancer Prostatic Dis, 2007, 10(1): 39-45.
［2］Zhao X, Guo Y, Yue W, et al. ABCC4 is required for cell proliferation and tumorigenesis in non-small cell lung cancer［J］. Onco Targets Ther, 2014, 7: 343-351.
［3］蒲聪颖，李珊，张媛媛. 肿瘤耐药性产生的分子机制研究进展［J］. 四川生理科学杂志, 2015, 11(2): 89-93.
［4］Kruh GD, Belinsky MG, Gallo JM, et al. Physiological and pharmacological functions of Mrp2, Mrp3 and Mrp4 as determined from recent studies on gene-disrupted mice ［J］. Cancer Meta Rev, 2007, 26(1): 5-14.
［5］高玮，张辉. 多药耐药相关蛋白3的研究进展［J］. 国际肿瘤学杂志, 2009, 8(4): 248-250.
［6］Russel F, Koenderink J, Masereeuw R. Multidrug resistance protein 4 (MRP4/ABCC4): a versatile efflux transporter for drugs and signalling molecules［J］. Trend Pharmacol Sci, 2008, 29(4): 200-207.
［7］Scheffer GL, Kool M, de Haas M, et al. Tissue distribution and induction of human multidrug resistant protein 3［J］. Lab Inves, 2002, 82(2): 193-201.
［8］Sciarra A, Schmidt S, Pellegrinelli A, et al. OATPB1/B3 and MRP3 expression in hepatocellular adenoma predicts Gd-EOB-DTPA uptake and correlates with risk of malignancy ［J］. Liver Int, 2019, 39(1): 158-167.
［9］Cirqueira CS, Felipe-Silva AS, Wakamatsu A, et al. Immunohistochemical assessment of the expression of biliary transportation proteins MRP2 and MRP3 in hepatocellular carcinoma and in cholangiocarcinoma ［J］. Pathol Oncol Res, 2019, 39(1): 158-167.
［10］Tada Y, Wada M, Migita T, et al. Increased expression of multidrug resistance-associated proteins in bladder cancer during clinical course and drug resistance to doxorubicin ［J］. Int J Cancer, 2002, 98(4): 630-635.
［11］Rady M, Mostageer M, Rohde J, et al. Therapy-relevant aberrant expression of MRP3 and BCRP mRNA in TCC-/SCC-bladder cancer tissue of untreated patients［J］. Oncol Rep, 2017, 38(1): 551-560.
［12］Hanada S, Maeshima A, Matsuno Y, et al. Expression profile of early lung adenocarcinoma: identification of MRP3 as a molecular marker for early progression［J］. J Pathol, 2008, 216(1): 75-82.
［13］Kuan CT, Wakiya K, Herndon JN, et al. MRP3: a molecular target for human glioblastoma multiforme immunotherapy ［J］. BMC Cancer, 2010, 10: 468.
［14］Cai C, Omwancha J, Hsieh CL, et al. Androgen induces expression of the multidrug resistance protein gene MRP4 in prostate cancer cells［J］. Prostate Cancer Prostatic Dis, 2007, 10(1): 39-45.
［15］He Z, Hu B, Tang L, et al. The overexpression of MRP4 is related to multidrug resistance in osteosarcoma cells ［J］. J Cancer Res Ther, 2015, 11(1): 18-23.
［16］Tomonari T, Takeishi S, Taniguchi T, et al. MRP3 as a novel resistance factor for sorafenib in hepatocellular carcinoma ［J］. Oncotarget, 2016, 7(6): 7207-7215.
［17］Wang LH, Ni CW, Lin YZ, et al. Targeted induction of apoptosis in glioblastoma multiforme cells by an MRP3-specific TRAIL fusion protein in vitro［J］. Tumour Biol, 2014, 35(2): 1157-1168.
［18］Kuan CT, Wakiya K, Herndon JN, et al. MRP3: a molecular target for human glioblastoma multiforme immunotherapy ［J］. BMC Cancer, 2010, 10: 468.
［19］Partanen L, Staaf J, Tanner M, et al. Amplification and overexpression of the ABCC3 (MRP3) gene in primary breast cancer ［J］. Genes Chromosomes Cancer, 2012, 51(9): 832-840.
［20］Rasmuson A, Kock A, Fuskevog OM, et al. Autocrine prostaglandin E2 signaling promotes tumor cell survival and proliferation in childhood neuroblastoma［J］. PLoS One, 2012, 7(1): e29331.
［21］Kochel TJ, Reader JC, Ma X, et al. Multiple drug resistance-associated protein (MRP4) exports prostaglandin E2 (PGE2) and contributes to metastasis in basal/triple negative breast cancer［J］. Oncotarget, 2017, 8(4): 6540-6554.
［22］Huynh T, Norris MD, Haber M, et al. ABCC4/MRP4: a MYCN-regulated transporter and potential therapeutic target in neuroblastoma ［J］. Front Oncol, 2012, 2: 178.
［23］He Z, Hu B, Tang L, et al. The overexpression of MRP4 is related to multidrug resistance in osteosarcoma cells ［J］. J Cancer Res Ther, 2015, 11(1): 18-23.
［24］Yu Z, Zhang C, Chai R, et al. Prognostic significance and molecular mechanism of ATP-binding cassette subfamily C member 4 in resistance to neoadjuvant radiotherapy of locally advanced rectal carcinoma［J］. PLoS One, 2014, 9(1): e85446.
［25］Lin S, Hoffmann K, Xiao Z, et al. MEK inhibition induced downregulation of MRP1 and MRP3 expression in experimental hepatocellular carcinoma ［J］. Cancer Cell Int, 2013, 13: 3.
［26］Kobayashi M, Funayama R, Ohnuma S, et al. Wnt-β-catenin signaling regulates ABCC3 (MRP3) transporter expression in colorectal cancer［J］. Cancer Sci, 2016, 107(12): 1776-1784.
［27］Ceballos MP, Decandido G, Quiroga AD, et al. Inhibition of sirtuins 1 and 2 impairs cell survival and migration and modulates the expression of P-glycoprotein and MRP3 in hepatocellular carcinoma cell lines［J］. Toxicol Lett, 2018, 289: 63-74.
［28］Brderdorf S, Zang S, Schaletzki Y, et al. cAMP regulates expression of the cyclic nucleotide transporter MRP4 (ABCC4) through the EPAC pathway ［J］. Pharmaco Geno, 2014, 24(10): 522-526.
［29］Porro A, Haber M, Diolaiti D, et al. Direct and coordinate regulation of ATP-binding cassette transporter genes by myc factors generates specific transcription signatures that significantly affect the chemoresistance phenotype of cancer cells ［J］. J Biol Chem, 2010, 285(25): 19532-19543.

[1]	LI Yanyang, WANG Yunjiao, LV Shichao. Effects and mechanism of traditional Chinese medicine injection in prevention and treatment of cardiotoxicity induced by antineoplastic drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 572-577.
[2]	LI Ruoning, GUO Zhanli, WANG Yuan, SUN Jianjun. Platelet-endothelial aggregation receptor 1 and its mediated signalling pathway Advances in the study of the role of platelets and endothelial cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 438-444.
[3]	WANG Siyu, LI Jiawei, LI Chenghao, LI Ling, GUO Qingyang, QIU Lu, ZHOU Shiqin, LIU Yongqi. Research progress of lactate dehydrogenase A in digestive system tumors and related drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 445-454.
[4]	LI Shan, LIU Yixin, REN Feifei, LI Xiangchen, ZHANG Zhiqing. Research progress of natural plant active ingredients in reversing tumor multidrug resistance by down-regulating P-gp [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 331-340.
[5]	WANG Dan, YAN Xiaoli, ZHANG Yuan. Helicobacter pylori infection influences the efficacy of immunotherapies for gastric cancer#br# [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 228-234.
[6]	ZHANG Wei, WANG Hongyuan, LEI Xiaohang, ZHAO Yingshuai, LV Weichao, ZHANG Jianguo. BCG + piroxicam versus BCG + gemcitabine for prevention of postoperative recurrence in intermediate- and high-risk bladder cancer and effects on serum AGR and PON1 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1146-1153.
[7]	LIU Dan, LIU Ming, JIN Liangyou, PAN Juan, XIN Haoru, LIU Mengyuan, LI Xin, ZHENG Kun, FENG Xiaoling. Research progress on the antitumor activity of costunolide [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1168-1176.
[8]	LIU Jiajun, QUE Zujun, TIAN Jianhui. Comparative study on the ability of active ingredients in Jinfukang to decrease neutrophils recruiting by lung cancer circulating tumor cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 1-9.
[9]	HUANG Hao, JIA Hong, WANG Xiaoshuang, ZHANG Lu, JIANG Hua. Effects of co-culture of dendritic cells loaded with MAGE-A3 antigen and cytokine-induced killer cells on tumor stem cells and malignant progression of endometrial cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 42-50.
[10]	GAO Lili, WANG Yuzhu, WANG Yan, LI Jian, WANG Jun. General considerations for clinical pharmacology of antitumor antibody-conjugated drugs: Implications from FDA review cases [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 75-85.
[11]	LIU Jiajia, GAO Yan, ZHANG Yehui, WU Jing. Functions of CRABP2 in tumorigenesis and progression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 86-92.
[12]	HONG Ziqiang, GOU Wenxi, CUI Baiqiang, BAI Xiangdou, JIN Dacheng, GOU Yunjiu. Role of the m7G methyltransferase METTL1 in tumours [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 93-100.
[13]	DU Jie, ZHAO Tingting, WANG Dalong, CHEN Xiaodong, LIU Kexin, WU Jingjing. Role and research progress of CYP46A1 in neurodegenerative diseases [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 925-935.
[14]	WANG Yali, HUO Xulei, CHEN Feng, LI Shenglan, ZHENG Xiaohong, WANG Can, LI Wenbin. Research progress on the antitumor effect of nifurtimox [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 955-960.
[15]	SHI Jingbin, XIONG Yang. Research progress on interaction between tumor microenvironment and breast cancer cells leading to tumor metastasis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 562-574.